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INTRODUCTION
Numerous studies have demonstrated that n-3 polyunsaturated fatty acids (PUFA), especially eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3), are associated with a reduced risk of developing several pathologies such as cardiovascular (1) , neurodegenerative (2) , inflammatory (3) diseases, and cancer (4) . Indeed, EPA and DHA are directly implicated in lipid metabolism by lowering triglyceridemia (5) but they are also precursors of eicosanoids with strong anti-inflammatory properties (3, 6) . Results from the latest French epidemiological study (7) have shown that, even if the consumption of total lipids was in line with the recommendations (34% of the total energy intake for 35-40% recommended), EPA and DHA consumption was at least 32% lower than the French guidelines (117 and 169 mg per day, respectively, for recommendations of 250 mg per day of each n-3 long-chain PUFA (n-3 LC-PUFA)) (8, 9) . In order to cover the n-3 LC-PUFA physiological needs, increasing EPA and DHA intakes represents a major nutritional challenge. One of the strategies consists in improving their bioavailability, without changing the total lipid intake. Several studies have demonstrated that lipid bioavailability depends on physicochemical factors of the dietary intake (10) (11) (12) (13) (14) . Indeed, nowadays, EPA and DHA are essentially consumed as oily fish for food intake or as fish oil (mainly triglycerides (TG) or ethyl esters (EE)) in food supplements. In the case of food supplements, the interest for marine phospholipids (PL) has recently increased. However, the limited data concerning the impact of the molecular lipid species (TG vs PL) of lipid intake on the n-3 LC-PUFA fate, leads to conflicting results. On the one hand, n-3 LC-PUFA levels were increased in the liver and brain of rats fed EPA and DHA in the form of PL compared to TG (15, 16) . On the other hand, accretion of DHA in rat liver, plasma and kidney was significantly lower when it was provided as PL (17, 18) .
Human studies were even less conclusive. In a double-blind, randomized, placebo-controlled, crossover study, a 4 week-consumption of 600 mg of n-3 LC-PUFA in PL increased the n-3 LC-PUFA levels in plasma and red blood cells (RBC) compared with the TG form (19) . In contrast, no effect of the molecular species of the dietary lipids (TG vs PL) was observed on n-3 LC-PUFA levels in plasma and RBC after 28 consecutive days of supplementation with 816 mg EPA per day and 522 mg DHA per day (20) . These contradictory results may account for different experimental designs, especially different EPA/DHA ratios, and prevent accurate comparison. Moreover, the impact of the molecular lipid species form was often studied by using fish oil for TG and krill oil for PL. However, it is worth noting that krill oil only provides 40-60% of n-3 PUFA in the form of PL, while the remaining fraction originates from TG and free fatty acids (FFA) (21, 22) . As a result, the role of PL as a lipid carrier on n-3 LC-PUFA metabolic fate is not clearly established. To our knowledge, only one study provided n-3 PUFA only as TG or as PL, and showed a better lymphatic absorption of n-3 LC-PUFA for rats fed PL vs TG (23) . However, PL were structured in liposomes while TG were provided as fish oil in bulk phase, so that the physical state of the two formulations was not comparable.
Thereby, the objective of the present study is to provide data on the digestibility and the intestinal absorption of n-3 LC-PUFA according to their molecular lipid species, only in the bulk oily phase.
Special attention was paid to ensure that the EPA/DHA ratio in the dietary lipid sources remained the same in order to ensure comparable results. n-3 LC-PUFA esterified in TG or PL were first subjected to an in vitro lipolysis in a titrimetric model. Intestinal absorption of n-3 LC-PUFA was studied in vivo in a rat lymph duct fistula model. The lipid and fatty acid compositions of the lymph were analyzed. It is worth noting that in vivo rodent models are considered as appropriate study models to assess oral compound bioavailability. They are often used in single dose protocols or supplementation studies (11, 12, 14, 23) . Indeed, similar physiological and physicochemical events, in particular those implying lipolytic enzymes, are described in both rodents and humans. Moreover, lymph analysis gives direct information on intestinal bioavailability, in contrast to blood, where the lipid composition may be contaminated by lipoproteins from liver metabolism. Thus, rat studies provide useful data to better understand the early stages of lipid digestion and investigate the intestinal bioavailability of FA of interest.
METHODS

Animals
Male Wistar rats (8 weeks-old, body weight: 300-350 g) were obtained from Elevage Janvier (Saint Genest sur l'Isle). All experiments were carried out in compliance with the ethic committee in 
Experimental design
Twenty-four hours before surgery, rats were fed a fat free diet (SAFE) with free access to water.
Each rat was placed under anesthesia by an intra-peritoneal injection of a ketamine/xylazine mixture (100/10 mg/kg, respectively; Axience). A polyethylene catheter (0.95 mm x 15 cm; Biotrol) was inserted into the main mesenteric lymph duct as described by Bollman et al.
and
Couëdelo et al. (12) . Immediately after surgery, rats were randomly assigned to one of the 3 experimental groups (6 rats/group), corresponding to one of the three n-3 LC-PUFA enriched formulations (TG n-3 , TG n-3 +PL veg , and TG veg +PL n-3 ). A volume, equivalent to 1 g of formulation,
was orally administrated by gavage, providing respectively 8.6 and 22.3 mg of EPA and DHA per rat. Each rat was then placed in an individual restraining cage (rat compartment 228 mm x 89 mm), in a warm environment with freely available water. After gavage, lymph was collected during 6 h in a collection tube stored in ice. To prevent pain, rats received an intra-peritoneal injection of buprenorphine (0.02 mg/kg; Axience) 1 h before and 2 h after surgery. At 6 h post-intubation, rats were euthanized by an intra-peritoneal injection of sodium pentobarbital (Axience) and lidocaine (Ceva).
Lipid formulations
The lipid formulations were prepared at room temperature under nitrogen in order to prevent PUFA oxidation. Three marine formulations were designed to provide a similar amount of FA, but differed by the chemical structure of lipids. More precisely, EPA and DHA were exclusively esterified either on TG or on PL molecules (Table 1) .
Marine PL were extracted from Lecimarin F50 (Novastell) by solvent fractionation using cold acetone. Briefly, 1 mL of chloroform/methanol (2/1, v/v) was added to 1 g of marine lecithin and maintained at room temperature until complete solubilisation. After addition of 20 mL of cold acetone (-20 °C), the sample was homogenized and then centrifuged (1050 g, 5 min, 4 °C; Sorvall ST-40R, Thermo Fisher Scientific). The supernatant, containing the neutral lipids, was removed and the pellet, containing the polar lipids was extracted twice with cold acetone and stored at -20 °C. Table 1 ). The glyceride structure of the marine oil mixture and of the marine PL was enzymatically determined according to methods described below. In the marine TG (oil mixture), EPA was mainly esterified in the sn-1/3 positions of marine TG (26% in the sn-2 position) whereas DHA was mainly located in the sn-2 position (50%). In marine PL, both EPA and DHA were essentially distributed in the sn-2 position (>74%) (see Supplementary data 1).
Lipid analysis
The total lipids were extracted from the lymph according to the procedure described by Folch et al. (27) . PL and TG fractions from the lipid extract were separated by thin layer chromatography (TLC, glass plates 20x20 cm pre-coated with silica gel 60H) using a solvent mixture composed of hexane/diethyl ether/formic acid (75/35/1, v/v/v). After vaporization of 2,7-dichlorofluorescein (2,7-DCF; Sigma-Aldrich) and visualization under UV-light, the spots corresponding to PL and TG were extracted from the silica gel by the addition of 2.5 mL of chloroform/methanol (2/1, v/v).
After homogenization and centrifugation of the scraped fractions (1050 g, 5 min, 20 °C), the organic phase containing lipids was collected. The extraction step was repeated by the addition of distilled water (100 µL) and chloroform/methanol (2/1, v/v, 2 mL) to the silica gel phase. Lipid extraction from the silica gel ended by the addition of 2 mL of methanol to the silica gel phase, homogenization and centrifugation. The overall organic phases were pooled and dried under nitrogen. Finally, 2,7-DCF was removed using 0. minutes. The injector and detector were maintained at 250 °C and 280 °C, respectively. GC peaks were integrated using Chromquest software (Thermofinnigan). FA were quantified using an internal ) )
The glyceride structure of lymph PL was achieved by phospholipase A2 (PLA 2 ) hydrolysis according to the Wolff et al (30) method, using PLA 2 from bee venom (600 -2400 U/g; 1U = 1 µEq FA/h; Sigma-Aldrich). Briefly, 150 µL of a PLA 2 solution (1 mg/mL; 3 mM CaCl 2 ) were added to wt.% of soya lecithin dissolved in a vegetable oil mixture (copra/palm/oleic sunflower oil; 6/30/63, w/w/w; TG veg +PL veg ) was also assessed as a control (see Supplementary data 2). Lipolysis experiments were performed in triplicate, for each formulation, i.e. TG n-3 , TG n-3 +PL veg , and TG veg +PL n-3 .
Characterization of lymph chylomicrons
The size of the lymph chylomicrons (CM) was measured for each rat group by dynamic light scattering using Vasco TM (Cordouan Technologies). Lymph samples were firstly diluted in a NaCl solution in water (0.9%, w/v). Experiments were performed considering a water refractive index of 1.331 and a viscosity of 0.888 cP. The real part and the imaginary part of particles were fixed at 1.47 and 0.01, respectively.
Statistical analysis
Data were expressed as mean values with standard deviation (mean ± SD). Intergroup comparisons were made on the basis of their respective mean. For the in vitro lipolysis experiment (n = 3), multiple comparisons were analyzed using a two-way ANOVA with two independent factors (lipid formulation and time of lipolysis) followed by a Bonferroni post-hoc test, using GraphPad Prism version 7. Data issued from the in vivo intestinal absorption experiment (n = 6) were compared by a one-way ANOVA test followed by a Tukey post-hoc test, using R version 3.5.1 (Rcommander package). P values lower than 0.05 were considered to be statistically significant.
RESULTS
In vitro digestion of n-3 LC-PUFA is modulated by their molecular lipid species of intake
Marine formulations (TG n-3 , TG n-3 +PL veg , TG veg +PL n-3 ) were subjected to in vitro lipolysis in a onestep static digestion model, with a focus on the duodenal lipolysis ( Figure 1) . Results revealed that all lipid formulations were well hydrolyzed during the time course of the lipolysis but to a different extent according to the formulation used (p time <0.001; p lipids =0.05 and p interaction <0.001; two-way ANOVA test). At the end of the lipolysis kinetics (60 minutes), the presence of soya lecithin in the marine formulation (TG n-3 +PL veg ) tended to inhibit the total lipolysis compared with TG n-3
(lipolysis level of 21.3% ± 4.7 and 14.5 ± 1.5, for TG n-3 and TG n-3 +PL veg , respectively). The lipolysis of TG n-3 +PL veg formulation was decreased by 47% when compared with the formulation free of n-3 LC-PUFA (lipolysis level of 14.5% ± 1.5 and 27.3% ± 1.9 for TG n-3 +PL veg and TG veg +PL veg , respectively; p<0.05). When n-3 LC-PUFA were esterified in marine PL (TG veg +PL n-
Influence of the molecular lipid species of the dietary lipids on the intestinal absorption of n-3 LC-PUFA
Six hours after lipid ingestion, no adverse effect was observed consecutive to lipid formulation intubation. The total FA concentration in the rat lymph was similar for the three marine formulations ( Table 2 ). The proportions of EPA and DHA in lymph total FA did not show statistical differences between all groups. Lymph TG and PL were separated and their FA compositions were analyzed separately ( Table 3 ). The relative proportions of lymph TG and PL were similar regardless of the molecular n-3 LC-PUFA carrier (p>0.05). Thereby, TG was the major lipid fraction (71% of total FA) while PL only represented 7% of total FA. Lymph TG presented a similar FA profile between the 3 groups (p>0.05). Saturated FA (SFA) and monounsaturated FA (MUFA) were the two major FA classes and PUFA were mainly represented by n-6 PUFA. Considering n-3 PUFA, EPA and DHA levels in lymph TG were similar in the 3 groups. In lymph PL, the incorporation of n-3 LC-PUFA and specifically EPA was quite low. DHA levels tended to be higher in the TG veg +PL n-3 than in TG n-3 and TG n-3 +PL veg (p=0.10). The proportions of the main FA esterified in the sn-2 position of lymph lipids were defined (Table 4) .
We noted that, SFA, MUFA and PUFA were equally distributed in the three positions of lymph TG for all groups. In lymph PL, SFA were mostly esterified in the sn-1 position and PUFA in the sn-2, irrespective of the groups. Considering n-3 LC-PUFA, EPA and DHA were mainly located in the sn-2 position of lymph PL regardless the molecular FA carrier (TG vs PL). DHA was equally esterified in the three positions of lymph TG when provided as marine TG (TG n-3 and TG n-3 +PL veg )
whereas it was mainly located in the sn-1/3 positions when ingested as marine PL (TG veg +PL n-3 ; p<0.001). More precisely, the intake of marine PL decreased by 46% the proportion of DHA esterified in the sn-2 position of lymph TG. However, EPA was mainly inserted in the sn-1/3
positions of lymph TG in all groups.
Characterization of lymph chylomicrons
Lymph chylomicrons were analyzed in terms of particle size. Data revealed that the mean diameter of CM were comparable between the 3 groups (223 ± 28, 248 ± 46 and 227 ± 47 nm for TG n-3 , TG n-3 +PL veg and TG veg +PL n-3 , respectively).
DISCUSSION
This study aims at evaluating the impact of the molecular lipid species of dietary n-3 LC-PUFA on (i) their in vitro digestibility and (ii) their intestinal bioavailability, in rats fed marine TG or PL.
Only few studies tried to couple in vitro lipid hydrolysis with in vivo absorption and they dealt with plant lipids (11, 12) . A recent study used marine lipids (32) . However, the formulations did not have a similar EPA/DHA ratio and did not allow comparison of PL as n-3 carrier or as emulsifier. In our work, lipid formulations were designed to provide a similar amount of EPA and DHA, esterified exclusively either in TG or in PL molecules. Because PL display surfactant properties that may influence lipid digestibility and absorption, a formulation containing soya lecithin instead of marine PL (TG n-3 +PL veg ) was also assessed. Results showed that even if the in vitro lipolysis level was dependent on the type of the formulation used, EPA and DHA were similarly absorbed, in vivo, regardless of the lipid carrier. However, they were differently distributed in lymph lipid fractions.
Specifically, when provided as marine PL, n-3 LC-PUFA tended to be better incorporated in lymph PL and DHA was more externalized in the glycerol backbone of lymph TG. To our knowledge, this is the first study analyzing the molecular structure of lymph lipid fractions using marine TG and PL as dietary n-3 LC-PUFA carriers.
Gastro-intestinal digestion can be considered as a limiting step of bioavailability. This is because dietary lipids first have to be hydrolyzed in the gastro-intestinal tract, before being absorbed by the intestinal brush border. In our study, we did not perform a gastric phase before the duodenal phase, which could be a limitation. However, (1) duodenal lipolysis represents nearly 70% of total lipolysis (33) and (2) TG veg +PL veg ) dramatically impaired the lipolysis rate, due to the molecular structure of EPA and DHA which led to a steric hindrance effect in in vitro studies (34, 35) . In agreement with other studies (12, 36) , we observed an inhibitory effect of soya PL (TG n-3 vs TG n-3 +PL veg ). This could be interpreted as an impediment of the binding of pancreatic lipase/colipase at the oil-water interface, decreasing TG availability for hydrolysis (37, 38) . Moreover, the PL nature influenced the lipid hydrolysis level (TG veg +PL veg vs TG veg +PL n-3 ). In our experiment, the porcine pancreas extract contained PLA 2 . It is well known that PLA 2 activity is modulated by the nature of the polar head group of PL and to a lesser extent by the FA nature, i.e. chain length or unsaturation degree (39, 40) .
Several studies using liposomes (41, 42) and emulsion droplets (43) showed that PLA 2 would preferentially bond to anionic PL rather than zwitterionic PL. Thus, in our study, a part of the decreased lipolysis observed with TG veg +PL n-3 formulation could be attributed to the PL composition (5% of anionic PL in PL n-3 vs 39% in PL veg ).
The products generated by the lipid hydrolysis (FFA, 2-MG, and lysophospholipids (lysoPL)) are micellized by biliary salts before being absorbed through the intestinal brush border. In the enterocytes, the lipolysis products are re-synthesized in TG and PL, compacted into CM to be released into the lymph compartment before reaching the bloodstream. In our experiment, the CM diameter was similar, whatever the molecular carriers used, suggesting that the structural properties of CM were neither impacted by the presence of PL in the formulation, nor by the molecular n-3 LC-PUFA carrier used, nor by the variations of lipolysis rates observed in vitro. This finding is in accordance with a previous study demonstrating that the lipid composition of CM did not differ in rats fed fish oil or marine PL (23) .
In all experimental groups, the FA quantification and FA profile of total lymph lipids were similar, suggesting that, under our test conditions, the digestion and the intestinal absorption of n-3 LC-PUFA were not modulated by the molecular n3 LC-PUFA carrier (TG n-3 vs PL n-3 ). Moreover, lymph lipids were mainly composed of PL and TG and the incorporation of EPA and DHA in lymph lipid fractions occurred independently of the molecular lipid species used (i.e. TG, PL, lysoPL, FFA) (23, (42) (43) (44) . Indeed, the FA profile of lymph TG revealed similar n-3 PUFA levels between the three groups, suggesting that EPA and DHA were incorporated in lymph TG regardless of the molecular FA carrier. However, in lymph PL, DHA levels tended to increase when provided as marine PL (TG veg +PL n-3 ) compared with the TG form of intake (TG n-3 and TG n-3 +PL veg ). This data agrees with a previous study where the proportions of n-3 LC-PUFA in CM-PL were increased with marine PL compared with fish oil (23, 32) . It has been suggested that FA absorption could be lower in anesthetized rats than in conscious animals. Nonetheless, the relative distribution of DHA in lymph lipid fractions is expected to be similar regardless of the consciousness state of the rats (44) .
The analysis of the glyceride structure of TG clearly showed that the molecular n-3 LC-PUFA carrier influenced the mechanisms involved in the re-synthesis of lymph lipids. In the enterocyte, lymph TG are mainly synthesized by the 2-MG pathway. We found that marine TG intake (TG n-3
and TG n-3 +PL veg ) led to an equimolar distribution of DHA in the three positions (33% of each) of lymph TG whereas the DHA provided was 56% esterified in the sn-2 position in marine TG formulation. This showed that the sn-2 position of the dietary TG was not fully conserved in lymph TG. A similar conclusion was drawn when structured TG rich in alpha-linolenic acid (ALA; 18:3 n-3) were used, i.e. only 50% of ALA located in the sn-2 position of dietary TG were recovered at this position in rat lymph TG (45) . This was interpreted as either (i) an isomerization of 2-MG into 1-MG prior to the lipolytic activity of pancreatic lipase (46) or (ii) a hydrolysis of the absorbed 2-MG by an intestinal lipase in the enterocyte (47) . This suggested that new metabolic pathways could take place as soon as the concentration of a lipid species varied greatly, thus ensuri g a "homeostat c"
state. On the contrary, in marine PL, DHA was exclusively (>74%) esterified in the sn-2 position of the glycerol backbone. After PL digestion, DHA was mainly released as FFA, due to a predominant activity of PLA 2 , specific of the sn-2 position of PL (48) . Thus, the presence of DHA in the sn-2 position of lymph TG suggested that the glycerol-3-phosphate (G3P) pathway was involved for the de novo TG synthesis using un-esterified DHA. Indeed, the G3P pathway could account for at least to be the 2-MG pathway, leading to the incorporation of a large part of free DHA on the 2-MG further affect its metabolic fate and tissue accretion. Indeed, previous reports indicated that using PL as n-3 LC-PUFA carriers can be more efficient than TG regarding the metabolization and hypoadipogenic effect of EPA and DHA (10, 15, 16, (49) (50) (51) . 
